AA
GPCR icon

Ancora Advisors’s Structure Therapeutics GPCR Stock Holding History

Ancora Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$482 Hold
10
– – ﹤0.01% 2291
2025
Q4 		$695 Buy
+10
New +$408 ﹤0.01% 2276

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Ancora Advisors's GPCR Position: Q1 2026 in Review

Ancora Advisors held its Structure Therapeutics (GPCR) position steady in Q1 2026 at 10 shares worth $482. The position accounts for ﹤0.01% of the portfolio, ranked #2291.

Ancora Advisors first reported a position in GPCR in Q4 2025 and has held it in 2 quarters since. The position peaked at $695 in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Ancora Advisors held 10 shares of Structure Therapeutics worth $482 as of Q1 2026.
  • Ancora Advisors left its Structure Therapeutics share count unchanged in Q1 2026.
  • Structure Therapeutics made up ﹤0.01% of Ancora Advisors's portfolio in Q1 2026, its #2291 holding.
  • Ancora Advisors first reported a position in Structure Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Ancora Advisors's Structure Therapeutics position peaked at $695 in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Ancora Advisors's 13F filing for Q1 2026, filed 15 May 2026.